NASDAQ : REVB
Revelation Biosciences, Inc. — Key statistics
Healthcare · Biotechnology · United States
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 2.30M |
| Enterprise Value | -8.44M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 569,059 |
| Shares Outstanding | 569,059 |
| Shares Change (YoY) | +2,741.10% |
| Shares Change (QoQ) | +19.38% |
| Owned by Insiders (%) | 18.24% |
| Owned by Institutions (%) | 2.35% |
| Float | 435,200 |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.22 |
| P/TBV Ratio | 0.22 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 6.21 |
| Quick Ratio | 6.11 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -154.77% |
| Return on Assets (ROA) | -78.73% |
| Return on Invested Capital (ROIC) | -96.27% |
| Return on Capital Employed (ROCE) | -106.14% |
| Weighted Average Cost of Capital (WACC) | 2.94% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.13M |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.06 |
| 52-Week Price Change | -88.43% |
| 50-Day Moving Average | 5.70 |
| 200-Day Moving Average | 8.05 |
| Relative Strength Index (RSI) | 40.05 |
| Average Volume (20 Days) | 23,639 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 6,605 |
| Short Previous Month | 1,581 |
| Short % of Shares Out | 1.16% |
| Short % of Float | 1.52% |
| Short Ratio (days to cover) | 0.17 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -11.27M |
| Pretax Income | -10.75M |
| Net Income | -19.20M |
| EBITDA | -11.24M |
| EBIT | -11.27M |
| Earnings Per Share (EPS) | -$58.18 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 11.48M |
| Total Debt | 739,916 |
| Net Cash | 10.74M |
| Net Cash Per Share | $18.88 |
| Equity (Book Value) | 10.07M |
| Book Value Per Share | 18.03 |
| Working Capital | 9.80M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -9.33M |
| Capital Expenditures | -111,507 |
| Depreciation & Amortization | 28,133 |
| Net Borrowing | n/a |
| Free Cash Flow | -9.44M |
| FCF Per Share | -$16.59 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -2,741.10% |
| Shareholder Yield | -2,741.10% |
| Earnings Yield | -1,436.52% |
| FCF Yield | -425.33% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $124.25 |
| Price Target Difference | 2,967.90% |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Oct 20, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:7 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |